Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Synthes guilty pleas

This article was originally published in The Gray Sheet

Executive Summary

Former Synthes CEO Michael Huggins and the company's current Director of Clinical and Regulatory Affairs John Walsh pled guilty in a Philadelphia federal court July 20 to one misdemeanor count of shipping adulterated and misbranded Norian XR bone cement product in interstate commerce. The execs were indicted June 16 as part of a broader case against Synthes and its Norian subsidiary (1"The Gray Sheet" June 22, 2009). Huggins and Walsh could each face up to a year in prison and a $100,000 fine. They are scheduled to be sentenced Oct. 22. Two other executives, Thomas Higgins, senior VP of global strategy, and Richard Bohner, VP of operations, also were indicted and await trial, according to the Philadelphia U.S. Attorney's office
Advertisement
Advertisement

Related Content

Topics

Advertisement
UsernamePublicRestriction

Register

MT027720

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel